Associated Papers
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M et al.
Cancers, 2023
37568719 (PubMed )
Supplement: cancers-15-03904-s001.zip › cancers-2478235-supplementary.pdf
Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms.
Kim HY et al.
Diagnostics (basel, Switzerland), 2022
Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice.
Minakawa K et al.
Journal of Hematology & Oncology, 2021
33785036 (PubMed )
Supplement: 13045_2021_1064_MOESM7_ESM.pdf
Detection of CALR Mutations Using High Resolution Melting Curve Analysis (HRM-A); Application on a Large Cohort of Greek ET and MF Patients.
Giannopoulos A et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2019
Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
Luque Paz D et al.
Blood Cells, Molecules & Diseases, 2018
Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.
Chi J et al.
Annals of Hematology, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H et al.
Haematologica, 2014
Select a paper to view details